STOCK TITAN

Connect Biopharma: early COPD failure rate 81% below placebo

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Connect Biopharma Holdings Limited (CNTB) reported preliminary Phase 2 Seabreeze STAT results for rademikibart in acute asthma and COPD, with plans to engage the FDA on potential Phase 3 programs in December 2026 for asthma and the first quarter of 2027 for COPD. In asthma, post-bronchodilator FEV1 improved 250 mL at Day 7 versus 120 mL with placebo (p=0.023). Through Week 4, the COPD treatment-failure rate was 81% lower, and emergency visits and hospital admissions for new exacerbations were reduced 100% versus placebo. The asthma treatment-failure rate was approximately 66% lower overall but did not reach statistical significance; using proposed Phase 3 entry criteria, the reduction was 86% (p=0.0282).

Cash, cash equivalents and short-term investments were $19.493 million at September 30, 2026, versus $44.342 million at December 31, 2025. Nine-month net loss widened to $52.832 million from $40.371 million; license and collaboration revenue rose to $3.673 million from $64,000, while research and development expense increased to $44.092 million from $26.516 million. Nasdaq cited 30 consecutive business days below the $1.00-per-share minimum bid. CNTB has an initial 180-calendar-day period, through May 11, 2027, to regain compliance, and its shares continue trading on the Nasdaq Global Market.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointCOPD treatment-failure rate was 81% lower through Week 4 versus placebo (p=0.0122).
  • Moderate pointAsthma post-bronchodilator FEV1 improved 250 mL at Day 7 versus 120 mL with placebo (p=0.023).

Negative

  • Moderate pointNine-month net loss increased to $52.832 million from $40.371 million.
  • Moderate pointNasdaq cited 30 consecutive business days below its $1.00-per-share minimum bid; CNTB has until May 11, 2027 to regain compliance.

Filing Explained

Nine-month license revenue of $3.7 million primarily reflected a regulatory milestone net of development cost sharing, and the Simcere agreement also provides eligibility for up to approximately $99 million in further milestone payments upon development, regulatory or commercial achievements, plus tiered royalties on Greater China sales.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash, cash equivalents and short-term investments $19.493 million As of September 30, 2026, versus $44.342 million as of December 31, 2025
Nine-month net loss $52.832 million Nine months ended September 30, 2026, versus $40.371 million in 2025
Nine-month license and collaboration revenue $3.673 million Nine months ended September 30, 2026, versus $64,000 in 2025
Nine-month research and development expense $44.092 million Nine months ended September 30, 2026, versus $26.516 million in 2025
Asthma FEV1 increase 250 mL versus 120 mL with placebo Post-bronchodilator FEV1 at Day 7 in the Phase 2 Seabreeze STAT asthma study; p=0.023
COPD treatment-failure rate reduction 81% Through Week 4 versus placebo in the Phase 2 Seabreeze STAT COPD study; p=0.0122
COPD emergency visits and hospital admissions reduction 100% For new exacerbations through Week 4 versus placebo; p=0.0137
Minimum bid price requirement $1.00 per share Nasdaq cited 30 consecutive business days with the bid price below this minimum
post-bronchodilator forced expiratory volume in one second (FEV1) medical
"250 mL increase in post-bronchodilator forced expiratory volume in one second (FEV1)"
registrational programs regulatory
"potential Phase 3 registrational programs"
A registrational program is a planned set of clinical trials and supporting studies designed specifically to provide the safety and effectiveness data regulators require to decide on marketing approval for a medical product. Think of it as the formal blueprint and evidence package companies build to gain a license to sell a drug or medical device; its progress and outcomes matter to investors because they determine if and when a product can reach the market and generate revenue.
Minimum Bid Price Requirement regulatory
"below the Minimum Bid Price Requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
interleukin-4 receptor alpha (IL-4Rα) medical
"targeting interleukin-4 receptor alpha (IL-4Rα)"
tiered percentage rates financial
"royalties at tiered percentage rates"
treatment failure rate medical
"an 81% reduction in the rate of treatment failure"
License and collaboration revenue (three months) $736,000 Compared with $16,000 for the three months ended September 30, 2025
License and collaboration revenue (nine months) $3.673 million Compared with $64,000 for the nine months ended September 30, 2025
Research and development expense (three months) $12.789 million Compared with $11.110 million for the three months ended September 30, 2025
Research and development expense (nine months) $44.092 million Compared with $26.516 million for the nine months ended September 30, 2025
General and administrative expense (nine months) $13.104 million Compared with $16.096 million for the nine months ended September 30, 2025
Net loss (three months) $16.150 million Compared with $17.200 million for the three months ended September 30, 2025
Net loss (nine months) $52.832 million Compared with $40.371 million for the nine months ended September 30, 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What happens if CNTB does not meet Nasdaq’s May 11, 2027 compliance deadline?

CNTB may be eligible for an additional 180-calendar-day compliance period if it does not regain compliance by May 11, 2027. Eligibility is contingent on factors including successfully transferring its listing to the Nasdaq Capital Market and meeting other Nasdaq listing requirements.

What safety results did CNTB report for rademikibart?

Rademikibart was reported as well tolerated in both Phase 2 Seabreeze STAT studies, with no new safety signals and fewer treatment-emergent adverse events and serious adverse events than placebo.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001835268false00018352682026-11-122026-11-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________
FORM 8-K
________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2026
________________________________________
Connect Biopharma Holdings Limited
(Exact name of Registrant as Specified in Its Charter)
________________________________________
Cayman Islands001-40212Not Applicable
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)(IRS Employer
Identification No.)
3580 Carmel Mountain Road, Suite 200
San Diego, California
92130
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (877) 245-2787
________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Ordinary Shares, par value $0.000174 per ShareCNTBThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 2.02 Results of Operations and Financial Condition.
On November 16, 2026, Connect Biopharma Holdings Limited (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 12, 2026, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), indicating that, for the last thirty consecutive business days, the bid price for the Company’s ordinary shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until May 11, 2027, to regain compliance with the Minimum Bid Price Requirement. The letter states that the Nasdaq staff will provide written confirmation of compliance if at any time during this 180-day period the closing bid price of the Company’s ordinary shares is at least $1.00 for a minimum of ten consecutive business days, subject to Nasdaq's discretion to require a minimum of up to 20 consecutive business days. The Nasdaq letter has no immediate effect on the listing or trading of the Company’s ordinary shares, and the Company’s ordinary shares will continue to trade on the Nasdaq Global Market under the symbol “CNTB.”
The Company intends to monitor the bid price of its ordinary shares and to consider available options if its ordinary shares do not trade at a level likely to result in the Company regaining compliance with the Minimum Bid Price Requirement by May 11, 2027.
If the Company does not regain compliance with the Minimum Bid Price Requirement by May 11, 2027, the Company may be eligible for an additional 180 calendar day compliance period, contingent upon various factors, including its ability to successfully transfer its listing to the Nasdaq Capital Market and meet other Nasdaq listing requirements.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1
Press Release of the Company, dated November 16, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CONNECT BIOPHARMA HOLDINGS LIMITED
Date:November 16, 2026By:/s/ Lisa Peraza
Name:Lisa Peraza
Title:Senior Vice President, Finance


Exhibit 99.1

Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update

– Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) –

– Plans to engage with the U.S. Food and Drug Administration (FDA) to gain alignment on potential Phase 3 programs for acute exacerbations of asthma in December 2026 and for COPD in the first quarter of 2027 –

SAN DIEGO, NOVEMBER 16, 2026 -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and nine months ended September 30, 2026, and provided a business update.

“We believe topline results from our Phase 2 Seabreeze STAT asthma and COPD studies mark a significant inflection point in the development of rademikibart as an add-on treatment to rescue bronchodilators and systemic corticosteroids for the treatment of acute exacerbations,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “Across both studies, rademikibart demonstrated clinically meaningful improvements in outcomes compared to placebo during the high-risk period following an acute exacerbation. In asthma patients receiving rademikibart there was a significant improvement in pulmonary function by Day 7 that was maintained through Week 4. There were no hospitalizations or emergency department visits through Week 4 in COPD patients receiving rademikibart, which was a 100% reduction compared to placebo. We believe these findings support the potential of rademikibart to redefine how acute exacerbations are managed, addressing both the acute event and the 4-week high-risk period following an exacerbation, to improve patient outcomes and reduce the substantial economic burden on healthcare systems. We are preparing to engage with the FDA to align on potential pivotal development programs for rademikibart for the treatment of acute asthma exacerbations next month followed by COPD in the first quarter of 2027.”

Recent Highlights

Development Highlights

•In September 2026, the Company reported preliminary topline data from the Phase 2 Seabreeze STAT asthma and COPD studies evaluating the safety and efficacy of rademikibart as an adjunct treatment for acute exacerbations. We believe results from both studies support advancement into Phase 3 development. The Company plans to meet with the FDA to gain alignment on potential Phase 3 registrational programs in asthma in December 2026 and for COPD in first quarter of 2027.

•Key Phase 2 Seabreeze STAT Asthma study (CBP-201-206) topline results include:

◦Rademikibart demonstrated a statistically significant improvement in lung function, with patients achieving a 250 mL increase in post-bronchodilator forced expiratory volume in one second (FEV1) at Day 7 compared to 120 mL with placebo (p=0.023) that was maintained through Week 4 (p=0.012).



◦Rademikibart reduced the treatment failure rate by approximately 66% over 28 days compared to placebo (p=0.153). The endpoint missed statistical significance due to an overall lower treatment failure rate than projected. The Phase 2 studies did not have an upper limit on pulmonary function at baseline. Using the proposed entry criteria planned for the potential Phase 3 program, which includes an upper limit of <80% for baseline percent predicted FEV1, the observed reduction in treatment failure rate was 86% (p=0.0282).

◦Rademikibart demonstrated a 50% reduction in emergency department or unscheduled medical visits for worsening asthma symptoms versus placebo.

•Key Phase 2 Seabreeze STAT COPD study (CBP-201-207) topline results include:

◦Rademikibart demonstrated significant reductions in COPD disease burden, including an 81% reduction in the rate of treatment failure (p=0.0122) and an 85% reduction in new moderate-to-severe exacerbations (p=0.0301) through Week 4 compared to placebo.

◦Rademikibart significantly reduced emergency department visits and hospital admissions for new exacerbations by 100% through Week 4 compared to placebo (p=0.0137), along with significant reductions in COPD symptoms and rescue inhaler use.

◦Rademikibart demonstrated a clinically meaningful improvement in lung function, with a 70 mL greater increase in FEV1 versus placebo at Week 4 (p=0.1607). We believe the smaller improvement in FEV1 in COPD patients was likely due to the substantially greater fixed airflow limitations and much lower responsiveness to bronchodilators in this population compared to asthma patients.

•Rademikibart was well tolerated in both Phase 2 Seabreeze STAT asthma and COPD studies, with no new safety signals, fewer treatment emergent adverse events and fewer serious adverse events than placebo.

Financial Results for the Three and Nine Months Ended September 30, 2026

•Cash, cash equivalents and short-term investments were $19.5 million as of September 30, 2026.

•License and collaboration revenues relate to the license agreement with Simcere, under which Simcere has been granted exclusive rights to develop, manufacture, and commercialize rademikibart for all indications in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. License and collaboration revenues for the three months ended September 30, 2026 were $0.7 million, primarily for cost reimbursements for development activities. License and collaboration revenues for the nine months ended September 30, 2026 were $3.7 million, primarily related to the achievement of a regulatory-based milestone, net of development cost sharing. License and collaboration revenues for the three and nine months ended September 30, 2025 were $16,000 and $64,000, respectively, for cost reimbursements for clinical materials. As a part of the Simcere license agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $99 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.

•Research and development expense for the three and nine months ended September 30, 2026 was $12.8 million and $44.1 million, respectively, compared with $11.1 million and $26.5 million,



respectively, for the same periods in 2025. The increase in research and development expense was primarily due to an increase in rademikibart-related development costs as a result of the initiation of the Phase 2 Seabreeze STAT asthma and COPD studies in May 2025.

•General and administrative expense for the three and nine months ended September 30, 2026 was $4.3 million and $13.1 million, respectively, compared with $6.6 million and $16.1 million, respectively, for the same periods in 2025. The decrease in general and administrative expense was primarily due to a decrease in professional fees, as the prior year periods included one-time professional fees to support our efforts to become more U.S.-centric, partially offset by an increase in non-cash, share-based compensation expense.

•Net loss for the three and nine months ended September 30, 2026 was $16.2 million, or ($0.26) per share, and $52.8 million, or ($0.87) per share, respectively, compared with $17.2 million, or ($0.31) per share, and $40.4 million, or ($0.73) per share, respectively, for the same periods in 2025.

About Rademikibart

Rademikibart is a next-generation fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), a common subunit of interleukin-4 receptor (IL-4) and interleukin-13 receptor (IL-13). The rapid onset of action was observed following the first dose of rademikibart in the Phase 2 maintenance asthma trial CBP-201-WW002, which differs from the clinical response observed with other biologics. In human cadaveric precision cut lung slices (PCLS), IL-13 reduced maximal β₂-agonist (formoterol)-induced bronchodilation by approximately 50%. Rademikibart restored approximately two-thirds of this loss, achieving maximal bronchodilation of 79% to 82%, with a consistent effect across the concentrations tested, whereas dupilumab and benralizumab produced partial and minimal recovery, respectively. We believe the unique binding of rademikibart with IL-4Rα has the potential to block the functions of IL-4 and IL-13 more effectively than first-generation products such as dupilumab, thereby potentially achieving improved treatment of T helper 2 related inflammatory diseases such as atopic dermatitis, asthma and COPD. However, head-to-head clinical studies comparing rademikibart to dupilumab, benralizumab or other products have not been conducted to date.

About Connect Biopharma

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company has completed global Phase 2 clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Based on the positive results from the completed Phase 2 studies, the Company plans to pursue both acute and chronic administration of rademikibart for asthma and COPD. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $99 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.

For more information visit www.connectbiopharma.com.

Forward-Looking Statements




This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our cash balance and cash runway, financial guidance, future financial and operating results and related expectations, business strategy and plans, prospective products (as well as their potential to achieve a differentiated, competitive, or favorable benefit or profile or trend relative to other products or otherwise, including on safety, tolerability, improvement, maintenance, clinical response, dosing, efficacy and/or convenience), statements regarding the timing or results of any interim analysis or interim, topline or preliminary data and whether such analysis or data is indicative of safety, efficacy, final trial results or likelihood of regulatory approval for our product candidates, planned or expected meetings with the FDA or any other regulatory authorities, planned or expected product approval applications or approvals, anticipated milestones and milestone payments, expected data readouts and enrollments and the timing thereof, research and development plans and costs, potential future partnerships, expectations about existing partnerships, timing and likelihood of success, objectives of management for future operations, future results of anticipated product development efforts, adequacy of existing cash and potential partnership funding to fund operations and capital expenditure requirements, anticipated patient populations, market opportunities and potential pricing strategies for our prospective products, if approved, our plans for rademikibart, including potential indications, as well as statements regarding industry trends. These statements are based on management’s current expectations of future events only as of the date of this press release and are inherently subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among other things: our ability to continue as a going concern; our ability to regain compliance with the continued listing requirements of Nasdaq; the sufficiency of our current cash, cash equivalents and short-term investments to fund our operations; the timing and amount of actual expenses, including, without limitation, our anticipated combined U.S. GAAP R&D and G&A expenses; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; whether we will need expanded or additional trials in order to advance rademikibart into Phase 3 development or to obtain regulatory approval for rademikibart or any of our future product candidates; the timing and outcome of any meetings with the FDA or other regulatory authorities regarding further development of our product candidates, including with respect to potential Phase 3 programs for rademikibart; whether the National Medical Products Administration (NMPA) approves Simcere’s pending New Drug Application for rademikibart for atopic dermatitis in China; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the U.S., the People’s Republic of China, Europe and other jurisdictions; our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; the degree of market acceptance of our product candidates, if approved, by physicians, patients, healthcare payors and others in the medical community, and the degree to which our product candidates reduce the economic burden on healthcare systems; the impact on our business of adverse global macroeconomic and geopolitical conditions, including high interest rates, the inflationary environment, recessionary fears, foreign exchange rate volatility, instability in financial institutions, government shutdowns, changes in monetary policy, changes in trade policies, including tariffs and other trade restrictions or the threat of such actions, and rising geopolitical instability, including the conflicts in Ukraine and the Middle East and the related volatility in the price of oil and other commodity prices; as well as the risks and uncertainties described in Part I, “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025, our subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC.




Words such as “aim,” “anticipate,” “believe,” “commitments,” “continue,” “could,” “design,” “estimate,” “expect,” “feel,” “goal,” “intend,” “may,” “might,” “objective,” “optimistic,” “plan,” “potential,” “predict,” “promising,” “seek,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its expectations, projections or plans will be achieved. Actual results or outcomes, or the timing of such results or outcomes, may differ materially from those expressed or implied in our forward-looking statements due to the risks and uncertainties described above. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated herein. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned not to place undue reliance on the scientific data presented or these forward-looking statements, which speak only as of the date hereof. Except as required by law, Connect Biopharma undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise.

This press release discusses our product candidate, rademikibart, which is under clinical investigation and has not yet been approved for marketing by the FDA, the NMPA, or by any other regulatory agency. No representation is made as to the safety or effectiveness of rademikibart for the uses for which it is being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only.







Connect Biopharma Holdings Limited
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)

Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
License and collaboration revenues
$
736 
$
16 
$
3,673 
$
64 
Operating expenses:
Research and development expense
12,789 
11,110 
44,092 
26,516 
General and administrative expense
4,259 
6,583 
13,104 
16,096 
Total operating expenses
17,048 
17,693 
57,196 
42,612 
Loss from operations
(16,312)
(17,677)
(53,523)
(42,548)
Total other income, net
182 
538 
819 
2,347 
Net loss before income tax
(16,130)
(17,139)
(52,704)
(40,201)
Income tax expense
20 
61 
128 
170 
Net loss
$
(16,150)
$
(17,200)
$
(52,832)
$
(40,371)
Basic and diluted net loss per ordinary share
$
(0.26)
$
(0.31)
$
(0.87)
$
(0.73)
Weighted-average ordinary shares outstanding, basic and diluted
62,974 
55,716 
60,825 
55,523 



Connect Biopharma Holdings Limited
Condensed Consolidated Balance Sheet Data
(in thousands)
(unaudited)
September 30, 2026
December 31, 2025
Cash, cash equivalents and short-term investments
$
19,493
$
44,342
Total assets
$
27,770
$
56,075
Total shareholders' equity
$
12,055
$
41,980





Investor Relations Contact:

Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802

Media Contact:

Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com

(858) 717-2310 or (646) 942-5604

Filing Exhibits & Attachments

4 documents

Keep reading